NDAORALTABLET
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
RECORLEV (levoketoconazole) by Bridge Therapeutics is cytochrome p450 11b1 inhibitors [moa]. First approved in 2021.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RECORLEV (levoketoconazole) is an oral cytochrome P450 11B1 inhibitor that reduces cortisol synthesis by blocking the enzyme 11β-hydroxylase. It is indicated for patients with Cushing's syndrome who require cortisol-lowering therapy. The drug represents a targeted approach to endocrine disorders where excess cortisol drives clinical pathology.
$0.01BPart D
Peak13.6 years to LOEProduct is in peak commercial phase with modest Part D utilization, suggesting a niche market with stable team structure and limited near-term headcount pressure.
Mechanism of Action
Cytochrome P450 11B1 Inhibitors
Pharmacologic Class:
Cortisol Synthesis Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RECORLEV offers stability in a niche, rare-disease market with strong patent protection through 2040, but limited scale limits career acceleration. The small patient population and modest sales ($10M Part D) mean smaller commercial teams compared to blockbuster products, making this role best suited for specialists seeking rare-disease expertise rather than high-velocity commercial growth.
Brand Manager
Worked on RECORLEV at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.